ArticleEmerging microbes & infections2025
A naturally occurring NS1 variant with effector domain deletion gains growth advantages in influenza virus infection.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular arms races at the virus-host splicing interface and their pathogenic implications.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High pathogenicity avian influenza virus (HPAIV) poses major threats to both poultry health and public safety. The viral nonstructural protein 1 (NS1) plays a crucial role in counteracting innate immunity. NS1 typically consists of approximately 230 amino acids with two domains: an RNA-binding domain (RBD) and the effector domain (ED). A novel naturally occurring NS1 variant, termed NS100, was reported herein, isolated during propagation of a recombinant H5N2 virus. NS100 encodes only the 1-95 residues of NS1, lacking the entire ED. Surprisingly, the NS100 virus replicated as efficiently as the wild-type (WT) virus in both cell and animal models. Cells infected with NS100 exhibited reduced interferon and cytokine expression, indicating preserved immune evasion capacity. Biochemical analyses revealed that NS100 retains key NS1 functions mediated by the RBD, including dsRNA binding, PKR interaction, and homodimer formation. In addition, NS100 cooperated with the viral RNA polymerase complex in a mini-genome assay, indicating functional synergy. Interestingly, the NS100 virus showed markedly reduced NS2 protein expression, likely due to impaired splicing caused by a GA transversion at a polypyrimidine tract. Transcriptome analysis further confirmed reduced splicing efficiency of NS transcripts and lower expression of antiviral host genes in NS100-infected cells. In conclusion, our findings demonstrate that NS1 can maintain essential pro-viral functions despite the loss of its ED, and that NS100 provides new insights into the modularity of NS1 and its broader role in regulating host-virus interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.